Evaluate Releases Orphan Drug Market Outlook Report Projecting Growth to $400 Billion by 2032

Evaluate has published the '2026 Orphan Drug Report,' revealing that the orphan drug market is expected to account for over 21% of global prescription drug sales by 2032, exceeding $400 billion. Key products such as Darzalex and Vyvgart are projected to lead the market, with Darzalex estimated at $31 billion in sales. While companies like Argenx and Merck are poised for high growth, Bristol Myers Squibb faces challenges due to patent expirations. Policy incentives such as the Inflation Reduction Act (IRA) and the reauthorization of Priority Review Vouchers (PRV) continue to support orphan drug innovation.